Altamira Therapeutics Completes $12 Million Public Offering
Altamira Therapeutics Ltd. (Nasdaq: CYTO), recognized for its pioneering RNA delivery technology, has successfully finalized its public offering. This initiative garnered an impressive total of $12 million, including an upfront payment of $4 million and the possibility of an extra $8 million through milestone-linked warrants.
Public Offering Details
The offering included 5,555,556 common shares, accompanied by pre-funded warrants and Series A-1 and Series A-2 common warrants. Each share was priced at $0.72, and the offering came with warrants that allow for purchasing an equal number of common shares. The Series A-1 common warrants are immediately exercisable and will expire either 18 months after they are issued or 60 days after significant biodistribution data for particular nanoparticles developed by the company is announced. On the other hand, the Series A-2 warrants will expire five years from the issuance date or six months after vital agreements concerning further product development are revealed.
Financial Expectations and Use of Funds
Altamira anticipates receiving around $4 million in gross proceeds from this offering, not counting placement fees and other costs. If the warrants are fully exercised, an additional $8 million could be added to the Company's funds. The money raised will mainly be directed towards supporting working capital and general corporate needs, helping to propel the Company’s innovative projects in the biotech sector.
Warrant Changes and Strategic Initiatives
Alongside the public offering, Altamira Therapeutics made strategic changes to existing warrants. Previously, warrants to buy up to 555,556 common shares at an exercise price of $9.00 were modified. Now, these warrants carry a new exercise price of $0.72 and will remain valid for five years following the offering's close. This change aims to boost shareholder value and make the warrants more appealing to investors.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is leading the charge in developing nanoparticle technologies based on peptides to enhance RNA delivery beyond the liver. The Company is progressing two key siRNA initiatives: AM-401 and AM-411, targeting KRAS-driven cancers and rheumatoid arthritis, respectively. Both programs are currently in the preclinical phase, showcasing the promising potential of the technology that the Company has nurtured since its founding in 2003.
Advancements in RNA Delivery
The OligoPhore™ and SemaPhore™ platforms are notable for their flexibility, enabling the delivery of various RNA types, including mRNA. Altamira has also opened its advanced delivery technology for out-licensing, facilitating collaboration with pharmaceutical and biotech companies eager to explore new therapeutic options.
Legacy Products and Future Plans
In addition to its pipeline, Altamira Therapeutics holds a significant 49% equity interest in Altamira Medica AG, which markets Bentrio®, an over-the-counter nasal spray for allergic rhinitis. As part of its strategic approach, the Company is looking into partnerships and divestments related to legacy assets for inner ear treatments, seeking opportunities that align with its future vision.
Frequently Asked Questions
How much money did Altamira Therapeutics raise in this offering?
Altamira Therapeutics raised a total of $12 million through this recent public offering.
What are the Series A-1 common warrants?
The Series A-1 common warrants permit the purchase of common shares at an exercise price of $0.72 and can be exercised immediately.
What’s the plan for the offering's proceeds?
The proceeds are earmarked for working capital and general corporate purposes to support ongoing and future initiatives.
Why were the existing warrants amended?
The amendments lowered the exercise price to $0.72, making them more appealing and accessible for investors.
What areas is Altamira Therapeutics targeting with its RNA delivery technology?
Altamira is focusing on developing treatments for KRAS-driven cancers and rheumatoid arthritis utilizing its innovative RNA delivery platforms.
